Publications by authors named "Lucie Rubio"
Pyruvate metabolism defects lead to severe neuropathies such as the Leigh syndrome (LS) but the molecular mechanisms underlying neuronal cell death remain poorly understood. Here, we unravel a connection between pyruvate metabolism and the regulation of the epitranscriptome that plays an essential role during brain development. Using genetically engineered mouse model and primary neuronal cells, we identify the transcription factor E4F1 as a key coordinator of AcetylCoenzyme A (AcCoA) production by the pyruvate dehydrogenase complex (PDC) and its utilization as an essential co-factor by the Elongator complex to acetylate tRNAs at the wobble position uridine 34 (U).
View Article and Find Full Text PDFA novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Pénélope Desroys du Roure Laurie Lajoie Aude Mallavialle Lindsay B Alcaraz Hanane Mansouri Lucie Rubio
J Immunother Cancer
January 2024
Article Synopsis
- Triple-negative breast cancer (TNBC) has a poor prognosis, and cathepsin D (cath-D) is a key target for antibody therapies to enhance natural killer (NK) cell activity against tumors.
- This study explored the effectiveness of engineered anti-cath-D antibodies in triggering NK cell-mediated attacks (ADCC) and their potential in combination therapies for TNBC.
- Results showed that the Fc-engineered antibodies activated NK cells and promoted ADCC against TNBC cells, suggesting their promise as a treatment strategy when used alongside other therapies.